The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy

Table 2 Univariate analysis results of progression-free survival in in 97 locally advanced esophageal squamous cell carcinoma patients who received curative concurrent chemoradiotherapy

Characteristics	No. of patients	Median PFS (months)	P value
Age
< 60 years	64 (66%)	15.6	0.044^a
≥ 60 years	33 (34%)	11.5
T status
1 + 2	15 (16%)	19.1	0.35
3 + 4	82 (84%)	11.9
N status
0 + 1	32 (33%)	20.3	0.38
2 + 3	65 (67%)	11.9
Stage
II + IIIA + IIIB	31 (32%)	16.5	0.93
IIIC	66 (68%)	11.5
Grade
1 + 2	71 (73%)	13.3	0.49
3	26 (27%)	14.0
Location
Upper	40 (41%)	14.6	0.76
Middle + Lower	57 (59%)	12.3
VEGF Day 0 (Mean: 176 pg/mL)
< 80	33 (34%)	14.2	0.20
> 80	64 (66%)	13.3
VEGF Day 5 (Mean: 163 pg/mL)
< 80	33 (34%)	18.2	0.39
> 80	64 (66%)	11.9
VEGF Day 28 (Mean: 195 pg/mL)
< 80	29 (30%)	20.1	0.029^a
> 80	68 (70%)	11.5
VEGF Day 5/Day 0 ratio
< 1	52 (54%)	15.0	0.46
> 1	45 (46%)	10.2
VEGF Day 28/Day 0 ratio
< 1	39 (40%)	16.3	0.55
> 1	58 (60%)	11.5
VEGF Day 28/Day 5 ratio
< 1	45 (46%)	18.5	0.029^a
> 1	52 (54%)	8.2

PFS progression-free survival; VEGF vascular endothelial growth factor; HR hazard ratio; CI confidence interval
^aStatistically significant

ISSN: 1471-2407